Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 27, Number 1—January 2021

Synopsis

Impact of Human Papillomavirus Vaccination, Rwanda and Bhutan

Iacopo BaussanoComments to Author , Felix Sayinzoga, Ugyen Tshomo, Vanessa Tenet, Alex Vorsters, Daniëlle A.M. Heideman, Tarik Gheit, Massimo Tommasino, Marie Chantal Umulisa, Silvia Franceschi, and Gary M. Clifford
Author affiliations: International Agency for Research on Cancer, Lyon, France (I. Baussano, V. Tenet, T. Gheit, M. Tommasino, M.C. Umulisa, G.M. Clifford); Ministry of Health, Kigali, Rwanda (F. Sayinzoga); Jigme Dorji Wangchuck National Referral Hospital, Thimphu, Bhutan (U. Tshomo); University of Antwerp, Antwerp, Belgium (A. Vorsters); Vrije Universiteit Amsterdam, Amsterdam, the Netherlands (D.A.M. Heideman); Centro di Riferimento Oncologico, Aviano, Italy (S. Franceschi)

Main Article

Table 1

Comparison of female students in HPV surveys, by selected characteristics, Rwanda baseline (2013–2014) and repeat (2017) surveys and Bhutan baseline (2013) and repeat (2017) surveys*

Characteristic Rwanda
 Bhutan
Baseline survey Repeat survey Baseline survey Repeat survey
All
   912
   1,087
973
 909
Age-group, y
17–18 374 (41.0) 536 (49.3) 285 (29.3) 347 (38.2)
19 274 (30.0) 326 (30.0) 337 (34.6) 303 (33.3)
20–22 264 (29.0) 225 (20.7) 351 (36.1) 259 (28.5)
χ2
 p<0.001
p<0.001
Place of birth
Capital   497 (54.5)   800 (73.6)   309 (31.8)   315 (34.7)
Outside capital   415 (45.5)   287 (26.4)   663 (68.2)   594 (65.3)
χ2
 p<0.001
p = 0.187
Place of living
With family or relative   763 (83.7)   936 (86.1)   798 (82.0)   765 (84.2)
Boarding school   149 (16.3)   151 (13.9)   175 (18.0)   144 (15.8)
χ2
 p = 0.127
p = 0.215
History of sexual intercourse
Never   720 (79.0)   729 (67.1)   871 (89.5)   760 (83.6)
Ever or prefer not to answer†   192 (21.0)   358 (32.9)   102 (10.5)   149 (16.4)
χ2
 p<0.001
p<0.001
Chlamydia trachomatis‡
Negative   892 (97.8)   1047 (96.3)   940 (96.6)   872 (95.9)
Positive   20 (2.2)   40 (3.7)   33 (3.4)   37 (4.1)
χ2
 p = 0.052
p = 0.437
HPV vaccination
No 519 (56.9) 125 (11.5) 77 (7.9) 45 (5.0)
Yes 393 (43.1) 962 (88.5) 896 (92.1) 864 (95.0)
χ2
 p<0.001
p = 0.009
Age at vaccination§
<14 12 (3.1) 412 (46.5) 12 (2.0) 569 (87.4)
>14 378 (96.9) 474 (53.5) 591 (98.0) 82 (12.6)
χ2
 p<0.001
p<0.001
No. doses§
1 NA 52 (5.5) NA 84 (9.9)
2–3 NA 901 (94.5) NA 769 (90.2)

*Values are no. (%) except as indicated. HPV, human papillomavirus; NA, not assessed.
†Includes 4 (Rwanda baseline), and 38 (Rwanda repeat), 43 (Bhutan baseline), and 20 (Bhutan repeat) students who preferred not to answer this question.
‡Detected by using E7 PCR bead-based multiplex genotyping assay.
§Does not add up to the total because of missing values.

Main Article

Page created: November 03, 2020
Page updated: December 21, 2020
Page reviewed: December 21, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external